Acuity's small-interfering RNA (siRNA) therapeutic, Cand5, has shown promise in an experimental model of macular degeneration.

Source: Inpharma, Volume 1, Number 1426, 2004 , pp. 8-8(1)

Publisher: Adis International

Keywords: Acuity-Pharmaceuticals; Age-related-macular-degeneration; Eye-disorder-therapies, pharmacodynamics; Small-interfering-RNA, pharmacodynamics; Trial-result-preclinical

Document Type: Short communication

Publication date: 2004-01-01

• In this: publication
• By this: publisher
• In this Subject: Pharmacology

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers